GenVec Ends Study
March 30, 2010 at 13:34 PM EDT
GenVec Inc. (Nasdaq: GNVC) ended a Phase 3 clinical trial of its pancreatic cancer treatment TNFerade saying that the drug was ineffective. Shares of the biopharmaceutical plummeted $2.02 to 79 cents.
